Skip to content
  • Tuesday, 27 October 2026
  • 4:29 pm
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • FDA Approves Pfizer’s Tukysa Regimen as Frontline Maintenance Therapy for Advanced HER2-Positive Breast Cancer
Pharmaceutical R&D

FDA Approves Pfizer’s Tukysa Regimen as Frontline Maintenance Therapy for Advanced HER2-Positive Breast Cancer

Teuku Ryan Oct 12, 2026 0

The United States Food and Drug Administration (FDA) has granted regulatory approval to Pfizer’s targeted oncology medication Tukysa (tucatinib) in…

Read More
Laboratory Automation & Robotics

Weekly Gilead and Merck oral HIV regimen maintains suppression in two phase 3 trials

Lana Keisha Jul 21, 2026 0

Recent findings presented at the 26th International AIDS Conference have underscored a significant advancement in HIV treatment, with an investigational…

Read More
Pharmaceutical R&D

Kyowa Kirin Secures FDA Approval for Enhanced Crysvita Dosing Regimen for Adults with X-Linked Hypophosphatemia

Teuku Ryan May 16, 2026 0

Kyowa Kirin has announced a significant advancement in the treatment landscape for X-linked hypophosphatemia (XLH) in adult patients, following the…

Read More
Solar-Powered Innovation: Turning the Global Plastic Crisis into a Sustainable Energy RevolutionUnlocking the Biological Clock: How Immune System Failures Drive the Aging ProcessDragonfly Vision Unlocks New Frontiers in Medical Technology Through Parallel EvolutionOsaka University Researchers Identify Essential Protein Complex for Sperm Development and Male Fertility
The Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals PlummetJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactEliquis Loss of Exclusivity: A Pharmaceutical Patent Cliff of Historic ProportionsMEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric Growth
Merck and Moderna’s cancer vaccine is customized for each patient’s tumorAn Unbiased Look at Google Gemini Omni: Features, Costs, and Market ComparisonESMO 2026: Sacituzumab Tirumotecan Sets New Survival Benchmark in Recurrent Endometrial CancerLight-Driven Magnetism Breakthrough Promises Ultrafast, High-Density Digital Data Storage
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Merck and Moderna’s cancer vaccine is customized for each patient’s tumor
Lana Keisha Oct 27, 2026
Data Science & Bioinformatics
An Unbiased Look at Google Gemini Omni: Features, Costs, and Market Comparison
Evan Lee Salim Oct 27, 2026
Pharmaceutical R&D
ESMO 2026: Sacituzumab Tirumotecan Sets New Survival Benchmark in Recurrent Endometrial Cancer
Teuku Ryan Oct 27, 2026
Advanced Materials Science
Light-Driven Magnetism Breakthrough Promises Ultrafast, High-Density Digital Data Storage
Nila Kartika Wati Oct 27, 2026

Copyright © 2026 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ